NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

treatment related mortality within 100 days from hematopoietic stem cell (HSC) infusion on day 0

Source null

→

primary · POSTED

Best disease response measured within 100 days from hematopoietic stem cell (HSC) infusion on day 0 using disease specific response criteria defined in the protocol

Source null

→

secondary · POSTED

Progression free survival defined as time from HSC infusion (day 0) until progression of disease or death due to any cause. Patients are censored if alive without disease progression through 1 year after HSC infusion

Source null

→

secondary · POSTED

Overall survival with events defined as death due to any cause and censored patients are alive as of 1 year post HSC infusion

Source null

→

secondary · POSTED

overall grade II-IV acute GvHD

2 participants died before they were eligible for this outcome

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-myelodysplastic-myeloproliferative-neoplasms
nct id: NCT00053989
trial label: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 5
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0000
source section id
NCT00053989-om-0000
source outcome index
0
endpoint
Day 100 TRM
endpoint definition
treatment related mortality within 100 days from hematopoietic stem cell (HSC) infusion on day 0
time origin
from start or conditioning (day -6 or -5) through day +100 after HSC infusion
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0001
source section id
NCT00053989-om-0001
source outcome index
1
endpoint
Day 100 Best Response
endpoint definition
Best disease response measured within 100 days from hematopoietic stem cell (HSC) infusion on day 0 using disease specific response criteria defined in the protocol
time origin
from start of conditioning on day -6 or -5 through day +100 after HSC infusion
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0002
source section id
NCT00053989-om-0002
source outcome index
2
endpoint
PFS
endpoint definition
Progression free survival defined as time from HSC infusion (day 0) until progression of disease or death due to any cause. Patients are censored if alive without disease progression through 1 year after HSC infusion
time origin
1 year
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0003
source section id
NCT00053989-om-0003
source outcome index
3
endpoint
OS
endpoint definition
Overall survival with events defined as death due to any cause and censored patients are alive as of 1 year post HSC infusion
time origin
1 year
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0004
source section id
NCT00053989-om-0004
source outcome index
4
endpoint
Acute GvHD
endpoint definition
overall grade II-IV acute GvHD
time origin
Day +100
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
2 participants died before they were eligible for this outcome
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0000
arm key
OG000
arm label
All Patients
regimen
All patients enrolled on study
analyzed count
41
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00053989-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0001
arm key
OG000
arm label
All Patients
regimen
All patients enrolled on study
analyzed count
41
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00053989-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0002
arm key
OG000
arm label
All Patients
regimen
All patients enrolled on study
analyzed count
41
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00053989-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0003
arm key
OG000
arm label
All Patients
regimen
All patients enrolled on study
analyzed count
41
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00053989-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
outcome key
om-0004
arm key
OG000
arm label
All Patients
regimen
All patients enrolled on study
analyzed count
39
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00053989-om-0004#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-myeloproliferative-neoplasms
nct id
NCT00053989
harm key
EG000
source section id
NCT00053989-ae
event group key
EG000
event group label
All Patients
serious affected
3
serious at risk
41
other affected
6
other at risk
41
frequency threshold
0
collection period
100 days
event definition
SAE=died before absolute neutrophil count recovery (DBE) or survived to day +28 without absolute neutrophil count recovery (FTE) AE=overall grade III-IV acute GVHD
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice